A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2008
At a glance
- Drugs Capsaicin (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Registrational; Therapeutic Use
- 19 Dec 2008 Based on the results of this trial and one other, the FDA has accepted a NDA for review, reported by NeurogenesX. The brand name Qutenza is awaiting approval.
- 25 Oct 2005 New trial record.